欢迎进入 投资云南@云南招商网

州市招商

文山

项目查询

关键字:
所属行业:
投资金额:
- 万元
 
您现在的位置是: 首页--生物医药和大健康--详细
昆明高新区新型疫苗产业园 New-type Vaccine Industrial Park in Kunming National Hi-tech Industries Development
发布时间:2017-07-12 15:56:29   来源:本站   作者:   点击:208次

Project Name

昆明高新区新型疫苗产业园
New-type Vaccine Industrial Park in Kunming National Hi-tech Industries Development Zone

Industry Involved

Biomedicine

Site

Kunming High-tech Industrial Development Zone

Project Overview

This park is to be established in the only national biological industry base of Yunnan Province recognized by the National Development and Reform Commission through an official reply. Located on the shore of Dianchi Lake and adjacent to the college town, it is provided with very convenient traffic. During the period of the “13th Five-Year Plan”, a new-type vaccine industrial park will be established relying on Institute of Medical Biology Chinese Academy of Medical Sciences, Walvax Biotechnology Co., Ltd., and other vaccine preparation enterprises. It is to carry out application researches mainly on medical virology, immunology and molecular biology, realize scale production of vaccines and immune products for major infectious diseases, form vaccine varieties with independent intellectual property and higher market share to become a national key R&D and production base of vaccines for infectious and epidemic diseases.

Content

Construction scale: This park covers a total floor area of about 800,000 m2, and involves the construction of R&D labs of new-type vaccines, standard production workshops, production exhibition halls, warehouses, office buildings, and ancillary facilities.

Construction duration:3 years

Land area: The overall planning land area of this project is 1,500 mu.

Supporting Conditions

1. Advantages and opportunities: Yunnan has the largest number of ethnic minorities, the most colorful ethnic culture, and the richest biological resources, natural medicines and ethical medicine resources in China. It possesses 6,559 kinds of traditional Chinese medical resources, accounting for 51.4% of the total number in China, more than 2,000 kinds of ethical medical resources, and over 10,000 folk recipes. This project is located in the national biological industry base of Yunnan Province, on the shore of Dianchi Lake, and adjacent to the college town. It is 12 km away from the municipal administrative center of Kunming and 40 km away from Kunming Changshui International Airport. With Kunming-Yuxi Expressway, Majinpu-Chengjiang Expressway, Huanhu East Road, lightrail and Pan-Asia Railway running through, it is provided with quite convenient traffic.

2. Associated industries: In 2016, the gross revenue of the core area of Kunming National Biological Industry Base in Kunming National Hi-tech Industries Development Zone reached RMB 40.8 billion, with a year-on-year growth of 12%. The output value of 16 single products from 247 bio-pharmaceutical and bioengineering enterprises led by Bayer AG, Hong Kong Jida Pharmaceutical Co., Ltd., Yunnan Baiyao Group Co., Ltd., KPC Pharmaceuticals, Inc., Walvax Biotechnology Co., Ltd., Kunming Longjin Pharmaceutical Co., Ltd., Sinopharm Yunnan Medical Devices Co., Ltd., Institute of Medical Biology Chinese Academy of Medical Sciences, Beijing Genomics Institute, CapitalBio, Daan Medical Test Institute, Suns Regenerative Medicine Engineering Co., Ltd., etc. exceeded RMB 100 million. This dominant industry - biological medicine & great health, has shown its obvious cluster advantage.

3. Early preparations: Around the development of biological medicine & great health industry, Kunming National Hi-tech Industries Development Zone will prepare the Convergence and Development Plan of Biological Medicine & Great Health Industry to promote the construction of one park (industrial park of biological medicine & great health) one valley (health care experience valley) and one center (exhibition center of biological medicine & great health). Land for this project has been reserved. Other project-related formalities are ongoing for approval.

Investment Estimate and Fund Raising

Investment estimate: The total project investment is expected to be RMB 5 billion and RMB 1 billion is required to be invested at the earlier stage.

Fund raising: bank loans and self-raising by enterprise

Preferential Policies Applicable

This project can enjoy the preferential policies in the Implementation Opinions of the General Office of the People's Government of Yunnan Province on Promoting Sound Development of Pharmaceutical Industry and the Collection of Policies for Kunming National Hi-tech Industries Development Zone in 2013, and related policies in the Notice of Administrative Committee of Kunming National Hi-tech Industries Development Zone on Issuance of Implementation Opinions on Quickening the Construction of "Yunnan Medicine" Industrial Base and Fostering "Yunnan Medicine" Characteristic Industrial Cluster.

Market Prediction (Analysis)

This project mainly targets at markets of vaccines for Children Program, self-paying vaccines for children, and adult vaccines. The compound annual growth rate of global vaccine industry from 2009 to 2014 is about 10.3%, while the annual growth rate of the Chinese market will be higher than the global average rate, up to about 15%. Along with in-depth researches on genomics, proteomics and immunology and constant improvement of such means as computer aided design (CAD), R&D of new vaccines will become process centering and flat-styled. The R&D cycle of a new-type vaccine will be shortened from current 10-12 years to 3-5 years, and the success rate will be increased from 30% to 50%. Then, R&D costs of enterprises can be reduced significantly, and more domestic enterprises will have a chance to develop therapeutic vaccines.

Profit Model and Preliminary Benefit Analysis

Upon the completion of this project, profits will be made through property rental and sales, as well as warehousing management. It is expected that, upon the completion, the annual average income can reach RMB 850 million and the payback period is 9 years (including construction period).

Risk Analysis

Possible fund chain risks and market risks during the development, construction and operation

Cooperation Pattern

Joint venture and cooperation

Contact Information

Contact Unit: Investment Promotion Bureau of Kunming City

Contact Person: Zhou Jing

Tel.: 0871-68155141

Fax: 0871-68155141

E-mail: gxqswb@163.com

关于我们| 商会平台| 信息公开| 联系我们 滇ICP备08002862号

0871-67195654/67195610

电子邮件:yunnanzs@163.com

云南招商官方微信

法制在线官方微信

管理员登录      不良信息报警      云南网监      网站备案      平台入口      招商大数据平台项目查询系统